Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Epigenetics|December 3, 2024
Genome-wide DNA methylation analysis reveals a unique methylation pattern for pleural mesothelioma compared to healthy pleura and other lung diseasesJanah Vandenhoeck, Joe Ibrahim, Nele De Meulenaere, et al.
ERJ Open Research|February 18, 2026
Differentiating benign and malignant solitary pulmonary nodules through exhaled breath analysisKathleen Zwijsen, Reinier R L Wener, Ellen Heirwegh, et al.
Frontiers in Immunology|April 7, 2023
Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesotheliomaMégane Willems, Arnaud Scherpereel, Eric Wasielewski, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|October 16, 2019
Mortality after lung transplantation: a single-centre cohort analysisJo Raskin, Arno Vanstapel, Eric K Verbeken, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2026
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)Omar Abdel-Rahman, Paul Taylor, Mary O'Brien, et al.
Molecular Oncology|November 14, 2025
Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologiesJanah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, et al.
The European Respiratory Journal|June 6, 2024
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205Jo Raskin, Veerle Surmont, Alexander P W M Maat, et al.
Future Oncology (London, England)|December 17, 2021
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistanceEgbert F Smit, Christophe Dooms, Jo Raskin, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 6, 2026
Optimizing COPD Care in Belgium: A Multidisciplinary Expert Consensus on Cardiopulmonary Risk ManagementNaomi Michotte, Fabian Demeure, Julien Guiot, et al.
JAMA Oncology|June 4, 2023
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical TrialJulien Mazieres, Paul K Paik, Marina C Garassino, et al.
Pageof 4